UNCY - Unicycive Therapeutics, Inc.
0.6371
0.032 4.960%
Share volume: 416,210
Last Updated: 05-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$0.61
0.03
0.05%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 05-16-2023 | 08-14-2023 | 11-14-2023 | 03-28-2024 | 05-13-2024 | 08-14-2024 | 11-13-2024 | |
| Total revenue | 675.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 675.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| -100.00% | nan% | nan% | nan% | nan% | nan% | |||
| Operating expenses | 4.877 M | 4.322 M | 5.938 M | 6.312 M | 9.204 M | 7.401 M | 6.251 M | |
| Selling general and admin | 1.847 M | 2.055 M | 2.566 M | 2.079 M | 2.391 M | 2.533 M | 3.206 M | |
| Research and development | 3.030 M | 2.267 M | 3.372 M | 4.233 M | 6.813 M | 4.868 M | 3.045 M | |
| Total expenses | 4.877 M | 4.322 M | 5.938 M | 6.312 M | 9.204 M | 7.401 M | 6.251 M | |
| -11.38% | 37.39% | 6.30% | 45.82% | -19.59% | -15.54% | |||
| Operating income | -4.202 M | -4.322 M | -5.938 M | -6.312 M | -9.204 M | -7.401 M | -6.251 M | |
| Ebit | -4.202 M | -4.322 M | -5.938 M | -6.312 M | -21.012 M | 9.409 M | -4.497 M | |
| Pretax income | -14.575 M | -3.838 M | -4.333 M | -7.798 M | -20.963 M | 9.855 M | -4.096 M | |
| -73.67% | 12.90% | 79.97% | 168.83% | -147.01% | -141.56% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -14.767 M | -4.441 M | -4.405 M | -6.931 M | 0.000 | 0.000 | 0.000 | |
| 69.93% | 0.81% | -57.34% | 100.00% | |||||
| Net income | -14.767 M | -4.441 M | -4.405 M | -6.931 M | -20.963 M | 9.855 M | -4.096 M | |
| 69.93% | 0.81% | -57.34% | -202.45% | 147.01% | -141.56% |
